Cargando…

CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for...

Descripción completa

Detalles Bibliográficos
Autores principales: Fennell, Brian J, McDonnell, Barry, Tam, Amy Sze Pui, Chang, Lijun, Steven, John, Broadbent, Ian D, Gao, Huilan, Kieras, Elizabeth, Alley, Jennifer, Luxenberg, Deborah, Edmonds, Jason, Fitz, Lori J, Miao, Wenyan, Whitters, Matthew J, Medley, Quintus G, Guo, Yongjing J, Darmanin-Sheehan, Alfredo, Autin, Bénédicte, Shúilleabháin, Deirdre Ní, Cummins, Emma, King, Amy, Krebs, Mark RH, Grace, Christopher, Hickling, Timothy P, Boisvert, Angela, Zhong, Xiaotian, McKenna, Matthew, Francis, Christopher, Olland, Stephane, Bloom, Laird, Paulsen, Janet, Somers, Will, Jensen, Allan, Lin, Laura, Finlay, William JJ, Cunningham, Orla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896602/
https://www.ncbi.nlm.nih.gov/pubmed/23995618
http://dx.doi.org/10.4161/mabs.26201
Descripción
Sumario:While myriad molecular formats for bispecific antibodies have been examined to date, the simplest structures are often based on the scFv. Issues with stability and manufacturability in scFv-based bispecific molecules, however, have been a significant hindrance to their development, particularly for high-concentration, stable formulations that allow subcutaneous delivery. Our aim was to generate a tetravalent bispecific molecule targeting two inflammatory mediators for synergistic immune modulation. We focused on an scFv-Fc-scFv format, with a flexible (A(4)T)(3) linker coupling an additional scFv to the C-terminus of an scFv-Fc. While one of the lead scFvs isolated directly from a naïve library was well-behaved and sufficiently potent, the parental anti-CXCL13 scFv 3B4 required optimization for affinity, stability, and cynomolgus ortholog cross-reactivity. To achieve this, we eschewed framework-based stabilizing mutations in favor of complementarity-determining region (CDR) mutagenesis and re-selection for simultaneous improvements in both affinity and thermal stability. Phage-displayed 3B4 CDR-mutant libraries were used in an aggressive “hammer-hug” selection strategy that incorporated thermal challenge, functional, and biophysical screening. This approach identified leads with improved stability and >18-fold, and 4,100-fold higher affinity for both human and cynomolgus CXCL13, respectively. Improvements were exclusively mediated through only 4 mutations in V(L)-CDR3. Lead scFvs were reformatted into scFv-Fc-scFvs and their biophysical properties ranked. Our final candidate could be formulated in a standard biopharmaceutical platform buffer at 100 mg/ml with <2% high molecular weight species present after 7 weeks at 4 °C and viscosity <15 cP. This workflow has facilitated the identification of a truly manufacturable scFv-based bispecific therapeutic suitable for subcutaneous administration.